N-of-One Selected by Admera Health to Provide Clinical Interpretation for the OncoGxOne 64-Gene Oncology Panel

N-of-One, Inc. recently announced that Admera Health has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne. N-of-One’s patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient’s molecular tests to therapeutic strategies, including clinical trials. Financial terms of the agreement are not disclosed.

The OncoGxOne is a next-generation sequencing (NGS) panel that detects 64 of the most common mutated genes found in several cancer types. Mutation types detected include single nucleotide variants, insertions and deletions, copy number variants and gene fusions associated with all current FDA-approved targeted therapies and multiple registered clinical trials. Results are delivered in an easy-to-interpret report providing physicians with the information necessary to practice precision medicine in a cost-efficient manner.

N-of-One clinical interpretation provides high-quality analysis of the results of each OncoGxOne test, identifying the most relevant therapeutic options for each patient based on the scientific and clinical evidence.

“We are very pleased to be able to offer N-of-One’s patient-specific analysis with our OncoGxOne cancer panel,” said James Dermody, PhD, Admera Health Lab Director. “Admera Health’s goal of easily integrating into routine clinical practice is supported by partnering with N-of-One. With N-of-One, we can provide oncologists with an Admera Health diagnostic report that is clear, actionable, and based on the latest scientific evidence. We are confident that we can quickly and efficiently provide the very best reports to our customers, so that they can provide the best care possible to their patients.”

“N-of-One is excited to be working with Admera Health to deliver a best-in-class, patient-specific solution to the market,” added Chris Cournoyer, CEO at N-of-One. “Our objective is to continue to provide the highest quality clinical interpretation to enable clinicians to reap the most value from Admera Health’s OncoGxOne panel. Ultimately, the patients and their physicians gain the greatest benefit from our working together.”

Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next-generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. For more information, visit www.admerahealth.com.

N-of-One is the leader in providing patient-specific therapeutic options for precision medicine in oncology by leveraging its world-class team of practicing oncologists and PhD scientists. The N-of-One team, coupled with proprietary technology and processes, enables N-of-One to analyze molecular diagnostic tests required to utilize this data at the point of care. Using N-of-One, laboratories can scale their molecular diagnostic programs with the highest quality clinical interpretation while still saving time and money. For more information, visit www.n-of-one.com.